NAT2 in Re-challenge of INH in Patients With Hepatitis

• Status: Unknown status
• Trial end date: 2015-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Apply the information of NAT2 genotyping into the re-challenge protocol of INH titration in patients with anti-TB medication induced hepatitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Collaborator: Department of Health, Executive Yuan, R.O.C. (Taiwan)
• Treatments: Isoniazid

Criteria

Inclusion Criteria:

• Older than 18 years-old

• Taken INH for more than 1 week

• Abnormal liver function

Exclusion criteria:

• Rule out the INH induced liver abnormality

• Existing reasons to cause liver abnormality other than TB-medication

• Taking drugs which interact with INH